The Hematology/Oncology Pharmacy Association has helped establish practical guidance for Investigational Services metrics and site utilization.

The metrics subgroup of the HOPA Investigational drug services (IDS) special interest group recently conducted a survey-based project to help establish practical guidance for IDS metrics and site utlity. Three surveys were sent to HOPA IDS professionals to document how metrics were currently gathered at various sites, categorize and define additional approaches, and create a list of recommended metrics for every IDS site to track. The recommended metrics can serve as a basis for standardization and benchmarking for sites mired in the complexity of research protocols.

The results have been published in the American Journal of Health-Systems Pharmacy.


Authors: Molly Schmidt, PharmD, BCPS, BCOP, CSP; Lisa Janssen Carlson, PharmD, BCOP; Jennifer Murphy, PharmD, BCOP, Sapna R Amin, PharmD, BCOP; Robin Lockhorst, PharmD, BCOP, BCPS; and Kyle Luedtke, PharmD

Read the abstract

An image of a doctor looking at an x-ray of lungs with cancer
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Zongertinib

Reyam Katchi, PharmD, PGY2 Hematology/Oncology Pharmacy Resident, and Kiera Roubal, PharmD, Oncology Clinical Pharmacist, break down the potential role for zongertinib in the treatment of non-squamous NSCLC with HER2 TKD activating mutations.

A graphic of a man's lungs on a blue background
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Taletrectinib

Benjamin Pastore, PharmD, PGY2 Adult Oncology Pharmacy Resident, and Jasmine Patel, PharmD, BCOP, Clinical Pharmacy Specialist - Thoracic Oncology, discuss the potential role of taletrectinib in the treatment of metastatic non-small cell lung cancer.

A line of women with breast cancer ribbons on their chests
Tools and Resources Drug Updates

Pharmacist's Application to Practice: Imlunestrant

Chan Tae Park, PharmD, PGY1 Pharmacy Resident, and Andrew Li, PharmD, BCOP, Oncology Pharmacist, dig into the potential role of imlunestrant (Inluriyo) in treating ESR1-mutated advanced/metastatic ER+, HER2- breast cancer.